With your own knowledge and the help of the following document:

Document 1 (Title: Preoperative Carotid Evaluation in Cardiac Surgery): Cerebrovascular events following coronary artery bypass grafting (CABG) represent a significant complication with substantial morbidity implications, prompting consideration of routine preoperative carotid assessment. Critical analysis of current evidence reveals important limitations in universal screening approaches despite their intuitive appeal. Systematic reviews document that only 8-12% of post-CABG strokes directly relate to carotid disease, with the majority resulting from cardioembolic events, aortic atheroembolism, or hypoperfusion mechanisms independent of carotid stenosis. Cost-effectiveness analysis demonstrates that universal carotid screening before CABG fails to meet established healthcare resource utilization thresholds, with numbers needed to screen exceeding 110 patients to prevent a single stroke. Contemporary clinical guidelines increasingly recommend selective rather than universal assessment based on individualized risk stratification incorporating neurological history, carotid auscultation findings, and stroke risk factor profiles. Prospective studies implementing targeted screening protocols demonstrate equivalent neurological outcomes compared to universal approaches while reducing resource utilization by approximately 62%. Multiple institutional reports indicate that limiting preoperative carotid evaluation to patients with prior neurological symptoms, carotid bruits, or multiple cerebrovascular risk factors effectively identifies clinically significant stenosis while avoiding unnecessary testing in low-risk populations. Notably, even when significant carotid stenosis is identified, the optimal management strategy remains controversial, with staged, combined, and deferred approaches all demonstrating comparable outcomes in selected populations. These findings from contemporary clinical evidence suggest that individualized, risk-stratified approaches to carotid assessment before CABG provide appropriate cerebrovascular risk evaluation while avoiding unnecessary testing for the majority of cardiac surgical candidates.
Document 2 (Title: Urinary Obstruction and Stasis   Kidney): The pressure within the renal pelvis is normally close to zero. When this pressure increases because of obstruction or reflux, the pelvis and calyces dilate. The degree of hydronephrosis that develops depends on the duration, degree, and site of the obstruction (Figure 12–4). The higher the obstruction, the greater the effect on the kidney. If the renal pelvis is entirely intrarenal and the obstruction is at the ureteropelvic junction, all the pressure will be exerted on the parenchyma (Klein et al., 2010). If the renal pelvis is extrarenal, only part of the pressure produced by a ureteropelvic stenosis is exerted on the parenchyma; this is because the extrarenal pelvis is embedded in fat and dilates more readily, thus "decompressing" the hydronephrotic left renal pelvis. Low density mass (P) in the left renal sinus had an attenuation value similar to that of water, suggesting the correct diagnosis. Unless intravenous contrast material is used, differentiation from a peripelvic cyst may be difficult. In the earlier stages, the renal pelvic musculature undergoes compensatory hypertrophy in its effort to force urine past the obstruction. Later, however, the muscle becomes stretched and atonic and decompensated. The progression of hydronephrotic atrophy is as follows (Chevalier, 2010; Rodriguez, 2004): 1. The earliest changes in the development of hydronephrosis are seen in the calyces. The end of a normal calyx is concave because of the papilla that projects into it; with increased intrapelvic pressure, the fornices become blunt and rounded. With persistence of increased intrapelvic pressure, the papilla becomes flattened, then convex (clubbed) as a result of compression enhanced by ischemic atrophy (Figure 12–5). The parenchyma between the calyces is affected to a lesser extent. The changes in the renal parenchyma are due to (a) compression atrophy from increased intrapelvic pressure (more accentuated with intrarenal pelves) and (b) ischemic atrophy from hemodynamic changes, mainly manifested in arcuate vessels that run at the base of the pyramids parallel to the kidney outline and are more vulnerable to compression between the renal capsule and the centrally increasing intrapelvic pressure. 2. This spotty atrophy is caused by the nature of the blood supply of the kidney. The arterioles are end arteries; therefore, ischemia is most marked in the areas farthest from the interlobular arteries. As the back pressure increases, hydronephrosis progresses, with the cells nearest the main arteries exhibiting the greatest resistance. 3. This increased pressure is transmitted up the tubules. The tubules become dilated, and their cells atrophy from ischemia. It should be pointed out that a few instances of dilated renal pelves and calyces are not due to the presence of obstruction. Rarely, the renal cavities are congenitally capacious and thus simulate hydronephrosis. More commonly, hydronephrosis may occur in childhood owing to the back pressure associated with vesicoureteral reflux. If the valvular incompetence resolves (and this is common), some degree of the hydronephrotic changes may persist. These persisting changes may cause the physician to suspect the presence of obstruction, which may lead to unnecessary surgery. A radioisotope renogram to assess ureteral drainage function can be performed to determine whether organic obstruction is present. 4. Only in unilateral hydronephrosis are the advanced stages of hydronephrotic atrophy seen. Eventually, the kidney is completely destroyed and appears as a thin walled sac filled with clear fluid (water and electrolytes) or pus (Figure 12–6).
Document 3 (Title: Nitroglycerin): Nitroglycerin is a vasodilatory drug used primarily to provide relief from anginal chest pain. Nitroglycerin has been FDA approved since 2000 and was first sold as a brand name agent. It is currently FDA approved for the acute relief of an attack or acute prophylaxis of angina pectoris secondary to coronary artery disease. Off label, non FDA approved uses include treatment for hypertensive urgency/emergency, coronary artery spasm, angina secondary to cocaine use, congestive heart failure (CHF), and chronic anal fissures. Along with hydralazine as a combination therapy, it is also indicated in patients with heart failure with reduced ejection in whom ACE inhibitors are contraindicated. Nitroglycerin is occasionally given to reduce radial spasms during coronary angiography through the radial approach. Nitroglycerin was first used in 1879 as a treatment for angina and since it has been part of management to relieve anginal chest pain.[1] Although nitroglycerin has a vasodilatory effect in both arteries and veins, the profound desired effects caused by nitroglycerin are primarily due to venodilation.[2] Venodilation causes pooling of blood within the venous system, reducing preload to the heart, which causes a decrease in cardiac work, reducing anginal symptoms secondary to demand ischemia. Arterial vasodilation will still occur and contribute to the relief of anginal symptoms.[3][4] Vasodilation of the coronary arteries will cause increased blood flow to the heart, increasing perfusion, but this effect remains minimal compared to the effects of venodilation.

Answer the following true/false question.
Question: Assessment of carotid artery stenosis before coronary artery bypass surgery. Is it always necessary?
Options:
A. True
B. False

Please respond **only** with a single valid JSON object in the following format:
{"answer": "True"}  ← if the answer is true
{"answer": "False"} ← if the answer is false
Do not include any other text or comments. Output must be strictly JSON.